News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Analysts call Precigen a buy after shares pulled back on Inovio Voceryq headlines.
  • Precigen Q3 Papzimeos revenue was $72.9M.
  • Precigen posted positive operating cash flow of $11.9M.
  • Analysts set an entry at $4.31 and a long-term target of $6.75 for PGEN.
  • Simpson Manufacturing is rated a buy for durable pricing power and improving cash conversion.
  • Simpson disclosed a $150M share buyback program.
  • Analysts propose entry $195.31, stop $175.00, target $235.00 for SSD over a multi-month horizon.

Latest Articles

XORTX Appoints New Director

XORTX Appoints New Director

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company focused on therapies for gout and kidney disease, announced the appointment of Depesh Narotam as an independent director on its board. Mr. Narotam brings over 20 years of financial services experience and will serve on the Compensation, Governance and Nominating Committee. The co…

Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence

Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence

Amarin Corporation plc announced its Q2 2026 financial results highlighting a 59% year-over-year global volume growth driven by its fully partnered international commercial strategy with Recordati S.p.A. and sustained market presence in the U.S. for VASCEPA. The company achieved lower operating expenses by 38%, completed a $70 million annual cost s…

TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies

TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies

TScan Therapeutics announced the dosing of the first patient in their Phase 3 ALLOHA-2 pivotal trial evaluating TSC-101, a TCR-engineered T cell therapy, in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) to prevent relapse post allogeneic hematopoietic cell transplantation. Positive safety and efficacy data from the …

Capital Bank Appoints Jay Como as Chief Operating Officer

Capital Bank Appoints Jay Como as Chief Operating Officer

Capital Bancorp, Inc. (NASDAQ: CBNK) announced the appointment of James 'Jay' Como III as Chief Operating Officer of its subsidiary, Capital Bank. Mr. Como brings over 20 years of financial services leadership with expertise in data governance, automation, and AI from his prior roles at T. Rowe Price and Silicon Valley Bank. His leadership is expec…

Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET

Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET

Aquestive Therapeutics will report its second quarter 2026 financial results after market close on August 11, 2026, followed by an investor conference call on August 12. The company will update on business developments including advancements in its proprietary Anaphylm and AQST-108 drug candidates. Aquestive operates as both a developer of propriet…

Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center

Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center

Silexion Therapeutics Corp. has initiated the Phase 2/3 clinical trial of its lead siRNA product candidate, SIL204, targeting locally advanced pancreatic cancer at Tel Aviv Sourasky Medical Center. This milestone follows regulatory approvals in Israel and Germany and marks the transition from regulatory preparation to active clinical execution. The…

Teva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting Continued Execution of Its Pivot to Growth Strategy

Teva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting Continued Execution of Its Pivot to Growth Strategy

Teva Pharmaceutical Industries Ltd. announced its Q2 2026 results showing a 1% revenue decline year-over-year primarily due to lower generic revenues but a 43% local currency growth in its key innovative brands to over $1 billion, including strong performances from AUSTEDO, AJOVY, and UZEDY. The company raised its 2026 revenue outlook for these inn…

VisionWave Files U.S. Non-Provisional Patent Application for DeepWave RF™, an AI-Powered Subsurface Sensing and Visualization Platform

VisionWave Files U.S. Non-Provisional Patent Application for DeepWave RF™, an AI-Powered Subsurface Sensing and Visualization Platform

VisionWave Holdings, Inc. announced the filing of a U.S. non-provisional patent application for its DeepWave RF™, an AI-driven subsurface sensing and visualization technology designed to provide anticipatory geological formation data ahead of the drill bit. This innovation aims to enhance drilling operations, improve hazard detection, and assist in…

VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates

VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates

VERAXA Biotech AG announced the filing of new patent applications for its BiTAC-TCE and BiTAC-ADC technology platforms and confirmed previously granted patents have cleared opposition. The strengthened patent portfolio includes over 50 patents across 14 countries and aims to provide protection for its core cancer therapy technologies through at lea…

Kirby Corporation Announces Second Quarter 2026 Results

Kirby Corporation Announces Second Quarter 2026 Results

Kirby Corporation reported Q2 2026 earnings per share of $1.67, consistent with the prior year and up 11% sequentially, with total revenues increasing 8% year-over-year to $922.4 million. The marine transportation segment saw revenues rise 9% due to stronger inland and coastal market fundamentals and higher barge utilization. Distribution and servi…

Dynamis Power Solutions Awards Baker Hughes Major Power Generation Order for Data Centers, Oil & Gas

Dynamis Power Solutions Awards Baker Hughes Major Power Generation Order for Data Centers, Oil & Gas

Baker Hughes has been awarded a major order by Dynamis Power Solutions for 76 NovaLT16 gas turbines, totaling approximately 1.3GW of hypermobile power generation capacity. These units will be deployed predominantly in data center and oil & gas applications, leveraging a modular design that offers high power density, operational flexibility, and low…

Wabash Announces Second Quarter 2026 Results

Wabash Announces Second Quarter 2026 Results

Wabash National Corporation reported second quarter 2026 revenues of $417 million, reflecting a 9.1% decline year-over-year amid strong shipments in the Dry Van market and growth in Parts & Services. The company posted a GAAP operating loss of $25 million and a non-GAAP adjusted loss of $24 million, including $1.8 million facility idling costs. Bac…

Eton Pharmaceuticals Announces Submission of Prior Approval Supplement to Expand Indication of KHINDIVI® (hydrocortisone) Oral Solution

Eton Pharmaceuticals Announces Submission of Prior Approval Supplement to Expand Indication of KHINDIVI® (hydrocortisone) Oral Solution

Eton Pharmaceuticals announced the submission of a Prior Approval Supplement to the FDA seeking to expand the approved indication of KHINDIVI (hydrocortisone) oral solution to include pediatric patients under five years old. The new formulation demonstrated bioequivalence to ALKINDI SPRINKLE, with potential FDA approval anticipated in the first hal…

ScottsMiracle-Gro Reports Third Quarter Results; Updates Full-Year Outlook Reflecting Accelerated EPS Growth

ScottsMiracle-Gro Reports Third Quarter Results; Updates Full-Year Outlook Reflecting Accelerated EPS Growth

ScottsMiracle-Gro released its Q3 fiscal 2026 earnings with $1.17 billion in net sales, a 1% increase year-over-year, showing steady progress toward its fiscal 2026 goals. Despite a 34% decline in GAAP EPS due to non-recurring charges, the company improved its non-GAAP adjusted EPS by 8%. The firm reaffirmed its outlook for low-single-digit U.S. ne…